Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Celldex Therapeutics

A biotechnology company focused on developing gene therapies for severe genetic diseases and cancer.

bluebird

A biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs.

AVEO

A biotechnology company that focuses on the discovery, development, and commercialization of synthetic DNA immunotherapies for the treatment of cancers and infectious diseases.

Inovio

A biopharmaceutical company that develops and commercializes innovative monoclonal antibody-based therapeutics for the treatment of cancer.

MacroGenics Inc

A biotechnology company focused on developing innovative antibody-based therapeutics for the treatment of allergic and inflammatory diseases.

Allakos

Celldex is a clinical stage biotechnology company focused on developing transformative therapeutics for severe inflammatory, allergic, autoimmune, and other devastating diseases.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 24, 2024 11:17 PM	4c938850
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 24, 2024 11:17 PM	33a493b9
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	7213c2e3
crunchbase profile	general
li profile	general	Feb 24, 2024 11:17 PM	aee4520e
translate crunchbase fundingrounds	general
peers	general
news basic	general	Feb 24, 2024 11:17 PM	67f3d1f5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CELLDEX

Celldex

Last Close

26.22

22/11 21:00

Market Cap

2.41B

Beta: -

Volume Today

662.65K

Avg: -